Molecular and Cellular Targets for Anti-Epileptic Drugs

A new phase of anti-epileptic drugs (AEDs) investigation has begun in which new drugs can be designed to target specific epileptogenic mechanisms. A rational approach to therapy today requires not only a full awareness of phamacokinetics of AEDs but also a thorough knowledge of their molecular targets and of their influence on excitatory and inhibitory mechanisms in the brain.